DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
QTRX logo

Quanterix Corporation Stock Price

NasdaqGM:QTRX Community·US$129.1m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

QTRX Share Price Performance

US$2.65
-1.68 (-38.80%)
​
US$3.00
Fair Value
US$2.65
-1.68 (-38.80%)
11.7% undervalued intrinsic discount
US$3.00
Fair Value
Price US$2.65
AnalystConsensusTarget US$3.00
AnalystLowTarget US$4.00
AnalystHighTarget US$4.00
Wed, 9 Sep 26
Fair ValueUS$3.00
Share Pricen/a

QTRX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$3 11.7% undervalued intrinsic discount

Biomarker Diagnostics And Proteomics Will Shape Future Markets

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$4 33.8% undervalued intrinsic discount

Life Sciences Challenges Will Limit Prospects But Synergies Will Aid

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$4 33.8% undervalued intrinsic discount

Ultra-sensitive Proteomics Will Revolutionize Early Disease Detection Worldwide

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
QTRX logo
Quanterix
11.7% undervalued intrinsic discount
Updated

Biomarker Diagnostics And Proteomics Will Shape Future Markets

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 9 Sep
Read Narrative
QTRX logo
Quanterix
33.8% undervalued intrinsic discount

Ultra-sensitive Proteomics Will Revolutionize Early Disease Detection Worldwide

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 12 Aug
Read Narrative
QTRX logo
Quanterix
33.8% undervalued intrinsic discount

Life Sciences Challenges Will Limit Prospects But Synergies Will Aid

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 7 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
QTRX logo

QTRX: Lowered Expectations And Coverage Milestones Will Shape Future Alzheimer’s Test Upside

Fair Value: US$3 11.7% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
QTRX logo

QTRX: Revised 2026 Guidance And Index Removal Will Support Stronger Earnings Power

Fair Value: US$4 33.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
QTRX logo

QTRX: Alzheimer’s Blood Test Progress Will Support Long-Term Upside Despite Recent Pessimism

Fair Value: US$4 33.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

2 Risks
1 Reward
View Full Analysis

Quanterix Corporation Key Details

US$153.4m

Revenue

US$85.0m

Cost of Revenue

US$68.4m

Gross Profit

US$191.5m

Other Expenses

-US$123.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-2.60
44.56%
-80.25%
0%
View Full Analysis

About QTRX

Founded
2007
Employees
450
CEO
Everett Cunningham
WebsiteView website
www.quanterix.com

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Recent QTRX News & Updates

User avatar
Narrative Update • Sep 09

QTRX: Lowered Expectations And Coverage Milestones Will Shape Future Alzheimer’s Test Upside

Analysts have lowered their price targets on Quanterix to $3 from $4, citing weaker Q2 results, a significant guidance cut, and ongoing commercial execution challenges in softer academic, government, and pharma end markets. Analyst Commentary Recent commentary on Quanterix points to a cautious stance from research desks.
Analysis Article • Aug 13

Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts

It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...

Recent updates

No updates

Quanterix Corporation Competitors

PALI logo

Palisade Bio

Symbol: NasdaqCM:PALI
Market cap: US$383.4m
ZNTL logo

Zentalis Pharmaceuticals

Symbol: NasdaqGM:ZNTL
Market cap: US$381.5m
TTRX logo

Turn Therapeutics

Symbol: NasdaqGM:TTRX
Market cap: US$377.1m
IPSC logo

Century Therapeutics

Symbol: NasdaqCM:IPSC
Market cap: US$374.8m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide